Here are the Evaluation of transplant pharmacist-led post-transplant hyperglycemia service journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Kohlman evaluation of living skills, evaluation of transplant pharmacist jobs, evaluation of transplant pharmacist led post transplant cancer, evaluation of transplant tv, evaluation of transplant pharmacist led post transplant things, ece evaluation of international transcripts, evaluation of transplant pharmacist led post transplant social groups, evaluation of transplant pharmacist led intervention.
Evaluation of transplant pharmacist-led post-transplant hyperglycemia service
Introduction: Uncontrolled post-transplant hyperglycemia (PTHG) can result in post-transplant diabetes mellitus (PTDM), therefore strict control of PTHG is warranted. PTDM affects 10%–40% of transplant recipients and increases morbidity and mortality. The objective of this study was to determine if pharmacy-led management of PTHG through a collaborative practice agreement (CPA) improves glycemic control.
Methods: Retrospective review of adults ≥18 years who received a kidney or liver–kidney transplant between January 2014 and December 2015 and April 2021 and October2022 in the pre- and post-CPA groups, respectively. Inclusion criteria were patients started on any anti-hyperglycemic agent within 1 month of transplant with 12 months of follow-up. Patients with type 1 diabetes mellitus, an insulin pump, other organ transplants, or treatment with high-dose corticosteroids for rejection were excluded. The primary outcome was a composite of hospitaliza tions and emergency department (ED) visits within 6 months of transplant due to PTHG. Secondary outcomes included hemoglobin A1c (HgbA1c) <7% and discontinuation of insulin at 6- and 12-month post-transplant, and time to first documented ambulatory PTHG assessment. Data were reported with descriptive statistics.
Results: Fifty-one and 53 patients in the pre- and post-CPA groups were included, respectively. Transplant pharmacists followed all patients in the post-CPA group. The primary outcome occurred in three patients (5.9%) in the pre- and no patients in the post-CPA groups (p = 0.083), respectively. More patients in the post-CPA group achieved a HgbA1c <7% at 6 months (31.7% vs. 68.1%; p = 0.007) and 12 months (22.7% vs. 58.3%; p = 0.004) using the last HgbA1c carried forward. More patients in the post-CPA group discontinued insulin at 12 months (7.1% vs. 30%; p = 0.02) and all anti-hyperglycemic agents by 6 months (2% vs. 15.1%; p = 0.02).
Conclusion: The transplant pharmacy-led service increased access to care, numerically reduced hospitalizations and ED visits due to PTHG, achieved more HgbA1c <7%, and had less insulin use at 6- and 12-month post-transplant. © 2025 Pharmacotherapy Publications, Inc.
Authors : Ho K.; Cohen E.; Do V.; Girone G.; Marvin J.; Belfield K.
Source : John Wiley and Sons Inc
Article Information
| Year | 2025 |
| Type | Article |
| DOI | 10.1002/jac5.2073 |
| ISSN | 25749870 |
| Volume |
You can download the article here
If You have any problem, contact us here